Skip to Main Content

The YODA ProjectThe YODA Project

    • Welcome
      • Policies
      • Development
      • Due Diligence Assessment
      • Data Use Agreement
      • Data Expiration
    • Project Leadership
    • Steering Committee
    • Roles & Responsibilities
      • Partnering with the YODA Project
        • Overview
        • Available Data
        • Data Release Pilot Project
      • Kenvue Brands LLC
        • Overview
        • Systematic Reviews
        • Approved Data Requests
      • QMUL
      • SI-BONE
    • Publications & Presentations
    • Announcements & Media Coverage
    • Relevant Literature
      • YODA Project Steering Committee and Stakeholders Conference
      • University College London and YODA Project Joint Meeting on Facilitating Data Access to Non-Industry Funded Research
    • Community Data Sharing Resources
    • FAQs
    • Acknowledgements
    • Contact Us
      • How To
      • Conflict of Interest
      • Data Use Agreement Training
    • Data Request Review Process
    • Request CSR Summary
    • Approved Data Requests
  • Trials
  • My Dashboard
    • YODA Project Metrics
      • Submitted Requests to Use Johnson & Johnson Data
      • Details of Data Requests
      • Clinical Trial Inquiries and CSR Summary Requests
      • Trials Determined to be Unavailable
  • Log in

Interleukin Inhibitors

NCT01369342 – A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Subjects With Moderately to Severely Active Crohn’s Disease (UNITI-2)

Posted on November 15, 2016 by tsuperadmin -

NCT01369329 – A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Subjects With Moderately to Severely Active Crohn’s Disease Who Have Failed or Are Intolerant to TNF Antagonist Therapy (UNITI-1)

Posted on November 15, 2016 by tsuperadmin -

NCT00771667 – A Phase 2b, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Ustekinumab Therapy in Subjects With Moderately to Severely Active Crohn’s Disease Previously Treated With TNF Antagonist Therapy

Posted on November 14, 2016 by tsuperadmin -

NCT01077362 – A Study of the Safety and Efficacy of Ustekinumab in Patients With Psoriatic Arthritis With and Without Prior Exposure to Anti-TNF Agents

Posted on July 28, 2015 by tsuperadmin -

NCT01009086 – A Study of the Safety and Effectiveness of Ustekinumab in Patients With Psoriatic Arthritis

Posted on July 28, 2015 by tsuperadmin -

  • «
  • 1
  • 2
  • 3
  • 4
  • 5

Side navigation

Site Map
Yale University logo
CORE - Center for outcomes, research, and evaluation Logo
  • Visit the YODA Project on Facebook
  • Visit the YODA Project on X

Accessibility at Yale

website designed by Gravity Switch